Bristol Myers Squibb (BMY) Other Non-Current Liabilities (2009 - 2026)
Bristol Myers Squibb (BMY) reported Other Non-Current Liabilities of $4.9 billion for Q1 2026, up 8.4% year-over-year from $4.5 billion in Q1 2025, and down 3.77% on a QoQ basis from $5.0 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Other Non-Current Liabilities data on file, last reported at $4.9 billion in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 8.4% year-over-year to $4.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 8.4% YoY) and the FY2025 annual result came in at $5.0 billion, up 12.84% from the prior year.
- Other Non-Current Liabilities retreated to $4.9 billion in Q1 2026 per BMY's latest filing, from $5.0 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $7.3 billion in Q1 2022 and bottomed at $4.5 billion in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $5.9 billion (2023), against an average of $5.8 billion.
- Peak annual rise in Other Non-Current Liabilities reached 15.46% in 2025, while the deepest fall reached 33.5% in 2025.
- Tracing BMY's Other Non-Current Liabilities over 5 years: stood at $6.6 billion in 2022, then retreated by 2.56% to $6.4 billion in 2023, then slumped by 30.4% to $4.5 billion in 2024, then climbed by 12.84% to $5.0 billion in 2025, then retreated by 3.77% to $4.9 billion in 2026.
- Per Business Quant, the three latest BMY Other Non-Current Liabilities figures stand at $4.9 billion (Q1 2026), $5.0 billion (Q4 2025), and $5.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.85 Bn |
| Dec 31, 2025 | 5.04 Bn |
| Sep 30, 2025 | 5.46 Bn |
| Jun 30, 2025 | 4.94 Bn |
| Mar 31, 2025 | 4.48 Bn |
| Dec 31, 2024 | 4.47 Bn |
| Sep 30, 2024 | 4.73 Bn |
| Jun 30, 2024 | 4.99 Bn |
| Mar 31, 2024 | 6.73 Bn |
| Dec 31, 2023 | 6.42 Bn |
| Sep 30, 2023 | 6.20 Bn |
| Jun 30, 2023 | 5.90 Bn |
| Mar 31, 2023 | 6.66 Bn |
| Dec 31, 2022 | 6.59 Bn |
| Sep 30, 2022 | 6.69 Bn |
| Jun 30, 2022 | 6.64 Bn |
| Mar 31, 2022 | 7.31 Bn |
| Dec 31, 2021 | 7.33 Bn |
| Sep 30, 2021 | 7.52 Bn |
| Jun 30, 2021 | 7.50 Bn |
| Mar 31, 2021 | 7.69 Bn |
| Dec 31, 2020 | 7.78 Bn |
| Sep 30, 2020 | 7.57 Bn |
| Jun 30, 2020 | 7.49 Bn |
| Mar 31, 2020 | 10.70 Bn |
| Dec 31, 2019 | 10.10 Bn |
| Sep 30, 2019 | 1.88 Bn |
| Jun 30, 2019 | 1.90 Bn |
| Mar 31, 2019 | 1.51 Bn |
| Dec 31, 2018 | 4.54 Bn |
| Sep 30, 2018 | 1.01 Bn |
| Jun 30, 2018 | 3.11 Bn |
| Mar 31, 2018 | 1.10 Bn |
| Dec 31, 2017 | 1.16 Bn |
| Sep 30, 2017 | 1.16 Bn |
| Jun 30, 2017 | 967.00 Mn |
| Mar 31, 2017 | 1.20 Bn |
| Dec 31, 2016 | 1.28 Bn |
| Sep 30, 2016 | 1.64 Bn |
| Jun 30, 2016 | 1.81 Bn |
| Mar 31, 2016 | 1.69 Bn |
| Dec 31, 2015 | 742.00 Mn |
| Sep 30, 2015 | 716.00 Mn |
| Jun 30, 2015 | 744.00 Mn |
| Mar 31, 2015 | 583.00 Mn |
| Dec 31, 2014 | 560.00 Mn |
| Sep 30, 2014 | 552.00 Mn |
| Jun 30, 2014 | 545.00 Mn |
| Mar 31, 2014 | 616.00 Mn |
| Dec 31, 2013 | 823.00 Mn |
| Sep 30, 2013 | 739.00 Mn |
| Jun 30, 2013 | 649.00 Mn |
| Mar 31, 2013 | 652.00 Mn |
| Dec 31, 2012 | 648.00 Mn |
| Sep 30, 2012 | 464.00 Mn |
| Jun 30, 2012 | 703.00 Mn |
| Mar 31, 2012 | 573.00 Mn |
| Dec 31, 2011 | 573.00 Mn |
| Sep 30, 2011 | 467.00 Mn |
| Jun 30, 2011 | 443.00 Mn |
| Mar 31, 2011 | 660.00 Mn |
| Dec 31, 2010 | 424.00 Mn |
| Dec 31, 2009 | 751.00 Mn |
| Sep 30, 2009 | 521.00 Mn |
| Jun 30, 2009 | 531.00 Mn |